Clinical trial
Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders
NCT00437086 · Mayo Clinic, Other · Completed
Key facts
| NCT number | NCT00437086 |
|---|---|
| Title | Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders |
| Official title | A Prospective Open-Label Pilot Trial of PS-341 (Bortezomib; VELCADE) for the Therapy of Symptomatic Advanced Myeloproliferative Disorders |
| Lead sponsor | Mayo Clinic, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Early Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Myeloproliferative Disorders, Leukemia |
| Intervention type | Drug |
| Interventions | PS-341 |
| Enrollment | 30 |
| Start date | Sep 1, 2005 |
| Primary completion | Nov 1, 2008 |
| Completion | Nov 1, 2008 |
| First posted | Feb 19, 2007 |
| Last update posted | Oct 17, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: